78th OREGON LEGISLATIVE ASSEMBLY – 2015 Regular Session MEASURE: HB 2028 A

## PRELIMINARY STAFF MEASURE SUMMARY

**Senate Committee on Senate Health Care** 

**REVENUE:** No revenue impact

FISCAL: Minimal fiscal impact, no statement issued

Action: Vote:

Yeas: Nays: Exc.:

**Prepared By:** Zena Rockowitz, Administrator

**Meeting Dates:** 5/13, 5/27

WHAT THE MEASURE DOES: Directs the State Board of Pharmacy to adopt rules that permit pharmacists to engage in the practice of clinical pharmacy. Defines "clinical pharmacy agreement" and "practice of clinical pharmacy." Permits health insurers to provide payment or reimbursement for services provided by the pharmacist through the practice of clinical pharmacy or pursuant to the statewide drug therapy management protocol. Limits participation from "practitioner" to physician. Adds Oregon Health Authority and coordinated care organizations to reimburse pharmacist or pharmacy under specified situations. States that for this statute, a pharmacist is classified as a primary care provider. Declares an emergency, effective on passage.

**CARRIER:** 

## **ISSUES DISCUSSED:**

**EFFECT OF COMMITTEE AMENDMENT:** No amendment.

**BACKGROUND:** Clinical pharmacy is where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness and disease prevention. Clinical pharmacists are part of a medical collaborative team, composed of physicians and other health care professionals. Oregon law permits collaborative drug therapy management to enable a pharmacist to participate in drug therapy, provided by a written agreement.

House Bill 2028-A allows for the practice of clinical pharmacy and patient care services. When authorized as part of a collaborative healthcare team, a pharmacist can provide patient care to include medication management, comprehensive medication review and post-diagnostic disease management services.